Exhibit 23.2


Consent of Independent Registered Public Accounting Firm


The Board of Directors
Sonnet BioTherapeutics, Inc.:


We consent to the use of our report included herein and to the reference to our firm under the heading “Experts” in the prospectus.


Our report dated November 27, 2019 contains an explanatory paragraph that states that Sonnet BioTherapeutics, Inc. has incurred recurring losses and negative cash flows from operations from inception, has a stockholders’ deficit of $2,845,487 as of September 30, 2019, and will require substantial additional financing to continue to fund its research and development activities that raise substantial doubt about its ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.


/s/ KPMG LLP  

Philadelphia, Pennsylvania
November 27, 2019